Thrombosis Clinical Trial
— MELODIEOfficial title:
A Prospective, Multicenter, Single Arm Study to Obtain Additional Data on the Safety and Efficacy of the Express Vascular LD Implantation in the Treatment of Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).
Status | Completed |
Enrollment | 150 |
Est. completion date | February 2007 |
Est. primary completion date | July 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - chronic symptomatic atherosclerotic disease in the iliac arteries (Fontaine Class IIa, IIb, and III) - atherosclerotic de novo or restenotic lesions in the common and/or external iliac artery. - baseline diameter stenosis of > or = 50% - reference vessel diameter > or = 5mm and < or = 10mm - at least one sufficient ipsilateral infrapopliteal run-off - length of diseased segment(s) < or = 10cm and can be treated with maximally two overlapping Express Vascular LD Stents. - multiple target lesions of the iliac arteries in the same patient can be included provided if each target lesion is compliant with the antiographic inclusion criteria and non-compliant with any of the antiographic exclusion criteria, target lesions are not located in the same target axis, and all target lesions can be treated during the same procedure. Exclusion Criteria: - chronic symptomatic atherosclerotic disease classified as fontaine Class I or IV - acute leg ischemia - pregnants patients - patients with uncorrected bleeding disorders (platelets < 150 000/mm3 or > 450 000 mm3, or patient who cannot receive anticoagulation or antiplatelet aggregation therapy - patient with known allergy to stainless steel - known anaphylactoid or other non-anaphylactic reactions to contrast agents that cannot be adequately premedicated prior to the index procedure - life-expectancy of less than 24 months due to other medical co-morbid condition that could limit patient's ability to participate in the study, the patient's compliance with the follow-up requirements or impact the scientific integrity of the study - patient currently participating in another study that has not yet completed the primary endpoint or that clinically interferes with the endpoint of this study - patients who have already participated in this study - patients with prior or planned bypass surgery of the target vessel - patient with prior stent placement in the target vessel - patient with any previous coronary intervention within the last 30 days before enrollment into this study or patients with planned coronary intervention within 30 days after enrollment into this study. - patients in whom the origin of the profunda femoris and superficial femoral artery is occluded in the limb supplied by the iliac artery to be treated without planned surgical repair - patients with heavily calcified and excessive tortuous lesions at the target site as determined by angiography - patients with target lesion which is within or adjacent to the proximal or distal segment of an aneurysm - patients with persistent, acute intraluminal thrombus of the proposed target lesion site post-thrombolytic therapy - patients with perforated vessels as evidenced by extravasation of contrast media - patients with multiple lesions in the same target vessels. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Limburgs Vaatcentrum Ziekenhuis Oost-Limburg | Genk | |
Belgium | Sint Trudo Hospital | Sint Truiden | |
Canada | CHUM- Notre Dame Hospital | Montreal | Quebec |
Czech Republic | General Teaching Hospital Prague | Praha | |
Czech Republic | Institute for Clinical and Experimental Medicine (IKEM) | Praha | |
Netherlands | Sint Antonius Hospital | Nieuwegein | CM |
Poland | University Hospital of Krakow | Krakow | |
Poland | University School of Medicine | Lublin | |
Poland | Center of Diagnostic Imaging and Vascular Disease Treatment | Szczecin | |
Poland | Samodzielny Publiczny Centraln Szpital | Warszawa |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation | KIKA |
Belgium, Canada, Czech Republic, Netherlands, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Angiographic mean percent loss of luminal diameter at 6 months post-procedure defined as ((post-procedure MLD - Follow-up MLD)/Post-procedure MLD) X 100 | |||
Secondary | hemodynamic success at hospital discharge, 30 days and 6, 12 and 24 months post-procedure, angiographic binary restenosis at 6 mont |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |